Browsing ICR Divisions by author "Parker, Chris"
Now showing items 1-20 of 42
-
A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.
Connell, SP; Hanna, M; McCarthy, F; Hurst, R; Webb, M; et al. (2019-05-20)Objectives To develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of providing diagnostic information of disease status prior to biopsy, and prognostic information for men on active ... -
A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy.
Verbeek, JFM; Nieboer, D; Parker, C; Kattan, MW; Steyerberg, EW; et al. (2019-04-22)Prostate cancer (PCa) testing involves a complex individually based decision making process. It should consider competing risks from other comorbidities when estimating a survival benefit from the early detection of ... -
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker, CC; Clarke, NW; Cook, AD; Kynaston, H; Catton, CN; et al. (ELSEVIER SCIENCE INC, 2024-06-01)BACKGROUND: Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised ... -
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Vale, CL; Fisher, D; Kneebone, A; Parker, C; Pearse, M; et al. (2020-09-28)BACKGROUND:It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively ... -
Advances in targeted alpha therapy for prostate cancer.
De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; et al. (2019-11)Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ... -
Advances in targeted alpha therapy for prostate cancer.
De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; et al.Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ... -
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; et al. (2017-05)Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ... -
appendix 8: Prostate cancer: eUpdate published online September 2016 (https://www.esmo.org/Guidelines/Genitourinary-Cancers).
Parker, C; Gillessen, S; Horwich, A; ESMO Guidelines Committee (2016-09) -
Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.
Merriel, SWD; Hetherington, L; Seggie, A; Castle, JT; Cross, W; et al. (2019-07)OBJECTIVES:To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS:A consensus statement was drafted on the basis of ... -
Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
Lovegrove, CE; Miah, S; El-Shater Bosaily, A; Bott, S; Brown, L; et al. (2020-01)Purpose We evaluated the performance of transrectal ultrasound guided systematic and transperineal template mapping biopsies with a 5 mm sampling frame stratified by the multiparametric magnetic resonance imaging Likert ... -
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis, L; Goranitis, I; Pirrie, S; Pope, A; Barton, D; et al. (2017-04)Objective To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Patients and methods Data on resource ... -
Current approaches to incorporation of radium-223 in clinical practice.
Parker, C; Heidenreich, A; Nilsson, S; Shore, N (2018-04)BACKGROUND:Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), ... -
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed, HU; El-Shater Bosaily, A; Brown, LC; Gabe, R; Kaplan, R; et al. (2017-02)Background Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric ... -
Diagnostic accuracy of the PROMIS study - Authors' reply.
Ahmed, HU; Brown, LC; Kaplan, R; Parker, C; Emberton, M (2017-07) -
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker, C; Zhan, L; Cislo, P; Reuning-Scherer, J; Vogelzang, NJ; et al. (2017-01)Symptomatic skeletal events (SSEs) commonly occur in patients with bone metastases, often leading to hospitalisations and decreased quality-of-life. In the ALSYMPCA trial, radium-223 significantly improved overall survival ... -
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker, C; Finkelstein, SE; Michalski, JM; O'Sullivan, JM; Bruland, Ø; et al. (2016-11)Background The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use.Objective To assess the efficacy and safety of radium-223 dichloride (radium-223) ... -
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
Stavrinides, V; Syer, T; Hu, Y; Giganti, F; Freeman, A; et al.Background False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such phenotypes in ... -
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; et al. (2017-02)Background Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding ... -
Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; et al. (2017-08)Context The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing.Objective In this collaborative review article, we examine recent literature regarding low-risk ... -
Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
Chakrabarti, D; Parker, CC (ELSEVIER, 2024-07-01)